45 results about "Colon cancer cell line" patented technology

Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, over-expression of GLDC in NIH / 3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers.

The invention discloses dehydroabietic acid benzimidazole derivatives with antitumor activity as well as a preparation method and an application of the dehydroabietic acid benzimidazole derivatives. The dehydroabietic acid benzimidazole derivatives I-a to I-l with the structures shown in a general formula I and pharmaceutically acceptable salt of the derivatives are shown in the description, wherein corresponding Aryl of dehydroabietic acid benzimidazole derivatives I-a to I-l are shown in the description respectively. Nitrogen-containing heterocyclic compounds are pharmaceutically acceptable salt of the dehydroabietic acid benzimidazole derivatives and have good antitumor bioactivity. Pharmacology experiments prove that the compounds have a remarkable inhibition effect on hepatoma cell lines SMMC-7721, breast cancer cell lines MDA-MB-231 and colon cancer cell lines CT26.

Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D3 and its analogs upregulate transcription of CAMP and defensin β2 (defB2) genes, leading to increased expression of hCAP18 mRNA and defB2. Induction of CAMP was observed in acute myeloid leukemia (AML), immortalized keratinocyte and colon cancer cell lines, as well as normal human bone marrow (BM)-derived macrophages and fresh BM cells. The present invention provides methods of inducing cathelicidin production by administering Vitamin D3 or Vitamin D3 analogs, as well as methods of treating skin infections and infections of the colon, sepsis and wound healing, preventing bacterial growth on skin grafts, promoting angiogenesis, and promoting chemoattraction by administering Vitamin D3 or Vitamin D3 analogs to upregulate cathelicidin and defensin expression.

The invention provides a human colon carcinoma cell line DXH-1, which is derived from primary lesion of human sigmoid colon carcinoma, and application of the human colon carcinoma cell line as a human colon carcinoma occurrence, human colon carcinoma development or human colon carcinoma transfer cell model, application of the human colon carcinoma cell line in establishing a human colon carcinoma animal model and application of the human colon carcinoma cell line in researching a human colon carcinoma occurrence mechanism and / or medicines for treating the human colon carcinoma. The human colon carcinoma cell line DXH-1 disclosed by the invention can be stably transferred for more than 50 generations, so that an appropriate material is provided for colorectal carcinoma mechanism and drug screening. In an in-vivo nude mice experiment, the human colon carcinoma cell line shows a relatively strong tumorigenesis cavity, and the cell line, transplanted subcutaneously in nude mice by 1*106 cells, is capable of promoting 100% (5 / 5) tumorigenesis after 35 days; the DXH-1 cell has certain drug resistance to colon carcinoma chemotherapeutics (5FU, such as oxaliplatin, irinotecan and the like), so that a material is provided to the researches on a colon carcinoma chemotherapeutic resistance mechanism; and the human colon carcinoma cell line DXH-1 is preserved in China Center for Type Culture Collection in Wuhan University, Wuhan, China with number of CCTCC No: C201543.

The present invention provides a class of compounds having a structure represented by a general formula 1, and a preparation method thereof, and applications in preparation of antitumor drugs. According to the present invention, the compound can significantly inhibit the growth of tumor cell lines (HepG-2, HT-29, Hela, BGC-823 and A549) while has low toxicity on Madin-Darby canine kidney (MDCK) cells, wherein the compound BH-26 has good anti-proliferative activity against colonic carcinoma cell line HT-29, human cervical cancer cell line Hela and human gastric cancer cell line BGC823 comparedto the positive drug cisplatin, and has significantly low cytotoxicity to normal Madin-Darby canine kidney (MDCK) cells compared to the positive drug cisplatin. The formula 1 is defined in the specification.

The invention discloses a mutated ubiquitin specific protease 33 gene and application of the mutated ubiquitin specific protease 33 (USP33) gene to production of a medicine for treating colorectal cancer. A research finds out that KDM5B has high expression in a colorectal cancer clinical sample and a colorectal cancer cell line and promotes the proliferation of colorectal cancer cells through inhibiting USP33. A KDM5B inhibitor or a monoclonal antibody of the KDM5B can be used for remarkably inhibiting the proliferation of the colorectal cancer cells. A further research proves that the KDM5B is combined with a USP33 gene promotor region, and the inhibition of the expression to the USP33 gene is realized through combining an upstream specific regulation and control sequence GCACA / C or G / TGTGC. The mutated ubiquitin specific protease 33 gene obtained through a site-directed mutation PCR (Polymerase Chain Reaction) technology can be used for resisting the inhibition effect of the KDM58B, so that the growth of the colorectal cancer cell line is inhibited.

The invention discloses a 1-(2,6-chlorphenyl)-3-substituted urea compound capable of acting on colon cancer, a preparation method and applications thereof. According to the present invention, the 1-(2, 6-dichlorophenyl)-3-(6-(substituted benzylamino)pyrimidine-4-yl) urea compound does not have toxic effect on the proliferation of BEAS-2B cells (normal lung cells), and has a certain inhibitory effect on three selected colon cancer cell lines including SW116 cells (human large intestine cancer cells), SW480 cells (human colon cancer cells) and SW620 cells (human colon cancer cells) so as to provide a certain antitumor activity.

Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, over-expression of GLDC in NIH / 3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers.

Identified herein is a novel post-translational modification of Mcm2, wherein the residue of serines 53 and 108 are phosphorylated. DDK phosphorylates Mcm2 at serines 53 and 108 when stimulated by Treslin. DDK is overexpressed in many human cancers, including colorectal cancer, suggesting that monitoring the phosphorylation of Mcm2 at serines 53 and 108 may detect early cancer with high sensitivity and specificity. It was also found that the homologous modification in budding yeast is required for DNA replication, and the modification occurs in cells during active DNA replication only. In an embodiment, the current invention is an antibody specific for human Mcm2 that is phosphorylated at serines 53 and 108. This antibody was found to be overexpressed in colon cancer cell line HCT 116, as well as other cancer cell lines, compared to normal cells.

The invention discloses a compound Chinese actinidia root Chinese medicinal composition and a preparation method and application thereof, belonging to the technical field of traditional Chinese medicines. The Chinese medicinal composition is characterized by comprising the following traditional Chinese medicines in parts by weight: 40-80 parts of Chinese actinidia root, 20-40 parts of salvia chinensis, 20-40 parts of herba scutellariae barbatae, 20-40 parts of herba oldenlandiae and 20-40 parts of giant knotweed. The compound Chinese actinidia root Chinese medicinal composition has remarkableproliferation inhibition effects on various cancer cells such as a hepatoma cell line Hep-G2, a lung cancer cell line NCI-H460, a gastric cancer cell line MGC-803, a breast cancer cell line MCF-7, a colon cancer cell line HCT-116 and the like, and can be used for reducing physical and psychological pains of a cancer patient in the chemo-treatment process and solving the problems of difficult and expensive administration.

The invention discloses a mutated ubiquitin specific protease 33 gene and application of the mutated ubiquitin specific protease 33 (USP33) gene to production of a medicine for treating colorectal cancer. A research finds out that KDM5B has high expression in a colorectal cancer clinical sample and a colorectal cancer cell line and promotes the proliferation of colorectal cancer cells through inhibiting USP33. A KDM5B inhibitor or a monoclonal antibody of the KDM5B can be used for remarkably inhibiting the proliferation of the colorectal cancer cells. A further research proves that the KDM5B is combined with a USP33 gene promotor region, and the inhibition of the expression to the USP33 gene is realized through combining an upstream specific regulation and control sequence GCACA / C or G / TGTGC. The mutated ubiquitin specific protease 33 gene obtained through a site-directed mutation PCR (Polymerase Chain Reaction) technology can be used for resisting the inhibition effect of the KDM58B, so that the growth of the colorectal cancer cell line is inhibited.

The invention discloses an astopic anti-hepatocarcinoma phage single-chained antibody HscFv 4-16 gene and appliance, which is characterized by the following: screening gene in the anti-hepatocarcinoma phage single-chained antibody store to select one astopic anti-hepatocarcinoma phage single-chained antibody HscFv 4-16; possessing high astopic reaction of anti-hepatocarcinoma scFv liver cancer cell system and human liver tissue with lowest combination drip rate than normal liver cell system, stomach cancer cell system and colonocarcinoma cell system by 256 times; making positive rate of reacting rate with human liver cancer tissue at 5.0 percent without combination reaction with normal liver tissue, esophagus cancer tissue and lung cancer tissue; reacting positive rate of liver cancer tissue higher than other tissues obviously. The invention possesses strong astopic property, which can be applied in kinds of liver cancer treatment drug and relative agent.

The invention discloses a recombinant plasmid containing MRP (Multidrug Resistance-associated Protein)-2 genes 3' UTR (Untranslated Region) and reporter genes and application thereof. Constructed MRP-2 gene 3' UTR and reporter gene carriers and pRL-SV40 carriers and microRNA (Ribonucleic Acid) to be screened are co-transfected into a drug-resistance colon cancer cell line; inhibitory activity of microRNA to MRP-2 gene 3' UTR region is responded by simultaneously detecting activities of firefly and renilla luciferase; and thus, a method for targeted screening of reversal tumor multidrug resistance microRNA is established. The method has excellent application prospect in aspects of screening the reversal tumor multidrug resistance microRNA, researching acting mechanism between the reversal tumor multidrug resistance and microRNA and researching the mechanism of the tumor cell multidrug resistance microRNA level.